Actinium Pharmaceuticals to Present Early Phase 1 Data for ATNM — 400 in Prostate Cancer at EANM
Actinium Pharmaceuticals will present early Phase 1 results for prostate cancer therapy ATNM-400 on October 19, 2026, at EANM in Vienna. Initial clinical data support advancing the non-PSMA-targeted radiotherapy for metastatic castration-resistant prostate cancer. ATNM-400 targets patients with low or absent PSMA expre